ASLAN Pharma of Singapore announced that its second in-licensed cancer drug, ASLAN002, was safe and well-tolerated in its initial Phase I trial. ASLAN002 is a small-molecule dual inhibitor of the cMET receptor tyrosine kinase and RON immune checkpoint that ASLAN in-licensed from Bristol-Myers Squibb. In addition, the company said ASLAN002 resulted in long-term stable disease and partial responses in specific tumor types. ASLAN plans to advance ASLAN002 into a Phase II trial in “highly selected” patients with gastric cancer in Asia Pacific centers.
Help employers find you! Check out all the jobs and post your resume.
